Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours
1996

Tenascin Expression in Ovarian Tumours

Sample size: 50 publication Evidence: moderate

Author Information

Author(s): KE Wilson, SP Langdon, AM Lessells, WR Miller

Primary Institution: ICRF Medical Oncology Unit and Department of Pathology, Western General Hospital, Edinburgh, UK

Hypothesis

Malignant ovarian tumours have increased expression of tenascin compared with benign tumours.

Conclusion

Malignant ovarian tumours show increased stromal expression of tenascin and a different RNA splicing pattern compared to benign tumours.

Supporting Evidence

  • Malignant and borderline tumours showed significantly greater incidence and intensity of stromal staining than benign tumours.
  • 9 out of 12 malignant tumours showed increased expression of larger tenascin RNA isoforms compared to benign tumours.

Takeaway

This study looked at a protein called tenascin in ovarian tumours and found that it is more common in cancerous tumours than in non-cancerous ones.

Methodology

The study examined tenascin expression in 50 ovarian tumours using immunohistochemistry and RT-PCR.

Limitations

The study had small sample sizes for some subgroups, which may limit the generalizability of the findings.

Participant Demographics

32 malignant, 7 borderline, and 11 benign ovarian tumours from 50 patients.

Statistical Information

P-Value

0.043

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication